S&P 500   4,293.93
DOW   33,833.61
QQQ   353.15
High Dividend REITs: Are They an Ideal Way to Diversify?
All Electric Commitment From GM, Volkswagen, Could Put Lithium Sector In A Supercycle (Ad)
Stock market today: European shares slip, Asian shares higher after Wall St's return to bull market
2 Dow Stocks Trading Less Than 10x Earnings are Blue Chip Values
Soaring EV Industry Keeps Investor Focus on Lithium (Ad)
The S&P 500 is in a bull market. Here's what that means and how long the bull might run
Boost for homebuyers: Average long-term US mortgage rate eases from 7-month high to 6.71% this week
All Electric Commitment From GM, Volkswagen, Could Put Lithium Sector In A Supercycle (Ad)
3 Mid Caps You Haven't Heard Of But Need To Know About
3 EV Stocks You Need To Have On Your Watchlist
S&P 500   4,293.93
DOW   33,833.61
QQQ   353.15
High Dividend REITs: Are They an Ideal Way to Diversify?
All Electric Commitment From GM, Volkswagen, Could Put Lithium Sector In A Supercycle (Ad)
Stock market today: European shares slip, Asian shares higher after Wall St's return to bull market
2 Dow Stocks Trading Less Than 10x Earnings are Blue Chip Values
Soaring EV Industry Keeps Investor Focus on Lithium (Ad)
The S&P 500 is in a bull market. Here's what that means and how long the bull might run
Boost for homebuyers: Average long-term US mortgage rate eases from 7-month high to 6.71% this week
All Electric Commitment From GM, Volkswagen, Could Put Lithium Sector In A Supercycle (Ad)
3 Mid Caps You Haven't Heard Of But Need To Know About
3 EV Stocks You Need To Have On Your Watchlist
S&P 500   4,293.93
DOW   33,833.61
QQQ   353.15
High Dividend REITs: Are They an Ideal Way to Diversify?
All Electric Commitment From GM, Volkswagen, Could Put Lithium Sector In A Supercycle (Ad)
Stock market today: European shares slip, Asian shares higher after Wall St's return to bull market
2 Dow Stocks Trading Less Than 10x Earnings are Blue Chip Values
Soaring EV Industry Keeps Investor Focus on Lithium (Ad)
The S&P 500 is in a bull market. Here's what that means and how long the bull might run
Boost for homebuyers: Average long-term US mortgage rate eases from 7-month high to 6.71% this week
All Electric Commitment From GM, Volkswagen, Could Put Lithium Sector In A Supercycle (Ad)
3 Mid Caps You Haven't Heard Of But Need To Know About
3 EV Stocks You Need To Have On Your Watchlist
S&P 500   4,293.93
DOW   33,833.61
QQQ   353.15
High Dividend REITs: Are They an Ideal Way to Diversify?
All Electric Commitment From GM, Volkswagen, Could Put Lithium Sector In A Supercycle (Ad)
Stock market today: European shares slip, Asian shares higher after Wall St's return to bull market
2 Dow Stocks Trading Less Than 10x Earnings are Blue Chip Values
Soaring EV Industry Keeps Investor Focus on Lithium (Ad)
The S&P 500 is in a bull market. Here's what that means and how long the bull might run
Boost for homebuyers: Average long-term US mortgage rate eases from 7-month high to 6.71% this week
All Electric Commitment From GM, Volkswagen, Could Put Lithium Sector In A Supercycle (Ad)
3 Mid Caps You Haven't Heard Of But Need To Know About
3 EV Stocks You Need To Have On Your Watchlist
NASDAQ:HARP

Harpoon Therapeutics (HARP) Stock Forecast, Price & News

$0.77
-0.01 (-1.28%)
(As of 06/8/2023 ET)
Compare
Today's Range
$0.74
$0.79
50-Day Range
$0.55
$0.82
52-Week Range
$0.54
$3.35
Volume
110,370 shs
Average Volume
173,370 shs
Market Capitalization
$24.72 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.71

Harpoon Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.71 Rating Score
Upside/​Downside
512.2% Upside
$4.71 Price Target
Short Interest
Healthy
1.72% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.61
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
Acquiring Shares
$10 M Bought Last Quarter
Proj. Earnings Growth
Growing
From ($1.11) to ($0.27) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.52 out of 5 stars

Medical Sector

110th out of 986 stocks

Biological Products, Except Diagnostic Industry

13th out of 163 stocks


HARP stock logo

About Harpoon Therapeutics (NASDAQ:HARP) Stock

Harpoon Therapeutics Inc. is a clinical-stage immunotherapy company at the forefront of revolutionizing cancer treatment and other diseases. The company is developing a novel T-cell engagers class to use the body's immune system to fight infection. 

Harpoon currently has several products in various stages of clinical trials, such as HPN328, which is in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors and HPN217, which is in Phase I/II clinical trials for the treatment of multiple myeloma.

Shares of Harpoon have skyrocketed following the release of data from its Phase 1 clinical trial for HPN217, a single-agent candidate for pretreated patients with relapsed/refractory multiple myeloma (RRMM). The data showed clinical activity and a "tolerable safety profile," with low-grade CRS observed in 29% of patients following the first or second doses of the drug and no incidents of "Grade 3 or higher CRS." Analysts have a consensus price target of $8.75 on the stock, suggesting over 85% upside potential.

Harpoon has a discovery collaboration and license agreement with AbbVie Biotechnology Ltd. to develop and commercialize products incorporating TriTAC platform technology and soluble T cell receptors. In addition, the company has a preclinical stage product, HPN601, for treating multiple solid tumor indications.

Receive HARP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Harpoon Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

HARP Stock News Headlines

All Electric Commitment From GM, Volkswagen, Could Put Lithium Sector In A Supercycle
More automakers are pledging to go "fully electric" by 2035. NOW is the perfect time to get in on the "EV Revolution." And the best way to potentially do that, is to skip over the overvalued electric vehicle stocks...
SVB Securities Remains a Buy on Harpoon Therapeutics (HARP)
Soaring EV Industry Keeps Investor Focus on Lithium
The need for lithium keeps going up, up, up with the mass adoption of electric vehicles. The lithium demand for EV batteries alone is now double the rate of lithium production.
See More Headlines

HARP Price History

HARP Company Calendar

Last Earnings
5/11/2023
Today
6/09/2023
Next Earnings (Estimated)
8/09/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:HARP
Fax
N/A
Employees
99
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$4.71
High Stock Price Forecast
$8.00
Low Stock Price Forecast
$1.50
Forecasted Upside/Downside
+512.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.71
Research Coverage
7 Analysts

Profitability

Net Income
$-67,730,000.00
Net Margins
-169.83%
Pretax Margin
-169.83%

Debt

Sales & Book Value

Annual Sales
$31.92 million
Book Value
$0.16 per share

Miscellaneous

Free Float
27,932,000
Market Cap
$24.72 million
Optionable
Not Optionable
Beta
1.55

Key Executives

  • Julia Marie Eastland
    President, Chief Executive Officer & Director
  • Frank J. Lanza
    Chief Financial & Accounting Officer
  • Holger WescheHolger Wesche
    Chief Scientific Officer
  • Luke N. Walker
    Chief Medical Officer
  • Chatan Charan
    SVP-Technical & Manufacturing Operations













HARP Stock - Frequently Asked Questions

Should I buy or sell Harpoon Therapeutics stock right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Harpoon Therapeutics in the last twelve months. There are currently 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" HARP shares.
View HARP analyst ratings
or view top-rated stocks.

What is Harpoon Therapeutics' stock price forecast for 2023?

7 Wall Street research analysts have issued 12 month price targets for Harpoon Therapeutics' shares. Their HARP share price forecasts range from $1.50 to $8.00. On average, they expect the company's stock price to reach $4.71 in the next year. This suggests a possible upside of 512.2% from the stock's current price.
View analysts price targets for HARP
or view top-rated stocks among Wall Street analysts.

How have HARP shares performed in 2023?

Harpoon Therapeutics' stock was trading at $0.7257 on January 1st, 2023. Since then, HARP shares have increased by 6.1% and is now trading at $0.77.
View the best growth stocks for 2023 here
.

Are investors shorting Harpoon Therapeutics?

Harpoon Therapeutics saw a decline in short interest during the month of May. As of May 15th, there was short interest totaling 417,700 shares, a decline of 45.1% from the April 30th total of 761,200 shares. Based on an average daily volume of 226,400 shares, the short-interest ratio is currently 1.8 days. Approximately 1.7% of the shares of the stock are short sold.
View Harpoon Therapeutics' Short Interest
.

When is Harpoon Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 9th 2023.
View our HARP earnings forecast
.

How were Harpoon Therapeutics' earnings last quarter?

Harpoon Therapeutics, Inc. (NASDAQ:HARP) posted its quarterly earnings results on Thursday, May, 11th. The company reported ($0.31) EPS for the quarter, beating the consensus estimate of ($0.42) by $0.11. The company had revenue of $8.58 million for the quarter, compared to analysts' expectations of $8.81 million. Harpoon Therapeutics had a negative trailing twelve-month return on equity of 473.13% and a negative net margin of 169.83%.

What is Gerald McMahon's approval rating as Harpoon Therapeutics' CEO?

5 employees have rated Harpoon Therapeutics Chief Executive Officer Gerald McMahon on Glassdoor.com. Gerald McMahon has an approval rating of 100% among the company's employees. This puts Gerald McMahon in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 100.0% of employees surveyed would recommend working at Harpoon Therapeutics to a friend.

What other stocks do shareholders of Harpoon Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Harpoon Therapeutics investors own include Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO), Alector (ALEC), Precision BioSciences (DTIL), Editas Medicine (EDIT), Gossamer Bio (GOSS), Kaleido Biosciences (KLDO), NVIDIA (NVDA), Ovid Therapeutics (OVID) and Advanced Micro Devices (AMD).

When did Harpoon Therapeutics IPO?

(HARP) raised $76 million in an IPO on Friday, February 8th 2019. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. Citigroup and Leerink Partners acted as the underwriters for the IPO and Canaccord Genuity and Wedbush PacGrow were co-managers.

What is Harpoon Therapeutics' stock symbol?

Harpoon Therapeutics trades on the NASDAQ under the ticker symbol "HARP."

Who are Harpoon Therapeutics' major shareholders?

Harpoon Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (1.14%), Renaissance Technologies LLC (0.52%), Acadian Asset Management LLC (0.30%), Sequoia Financial Advisors LLC (0.27%), Bailard Inc. (0.17%) and Two Sigma Investments LP (0.15%). Insiders that own company stock include Ansbert Gadicke, Bioventures 2014 LP Mpm, Georgia Erbez, Holger Wesche, Impact Fund (Cayman) Oncology and Ronald Hunt.
View institutional ownership trends
.

How do I buy shares of Harpoon Therapeutics?

Shares of HARP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Harpoon Therapeutics' stock price today?

One share of HARP stock can currently be purchased for approximately $0.77.

How much money does Harpoon Therapeutics make?

Harpoon Therapeutics (NASDAQ:HARP) has a market capitalization of $24.72 million and generates $31.92 million in revenue each year. The company earns $-67,730,000.00 in net income (profit) each year or ($1.74) on an earnings per share basis.

How can I contact Harpoon Therapeutics?

Harpoon Therapeutics' mailing address is 131 OYSTER POINT BLVD SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.harpoontx.com. The company can be reached via phone at (650) 443-7400 or via email at ir@harpoontx.com.

This page (NASDAQ:HARP) was last updated on 6/9/2023 by MarketBeat.com Staff

My Account -